Wave Life Sciences up on positive early-stage data from genetic disorder therapy

Wave Life Sciences

16/10/2024 15:28

** Shares of drug developer Wave Life Sciences  WVE.O  rise
71.7% to $14.4 
    ** Co announces positive early-stage trial data from its
genetic disorder therapy WVE-006 
    ** WVE-006 is a gene editing therapy that is given as an
under-the-skin injection to patients with alpha-1 antitrypsin
deficiency, a genetic disorder than can cause liver disease 
    ** Co says the therapy helped restore levels of a protein
which helps reduce symptoms associated with the disorder   
    ** "The data is impressive and represents demonstration of
historic first-in-human POC ADAR-mediated RNA editing and also
one that could clear regulatory hurdle in alpha-1 antitrypsin
deficiency," says Truist Securities 
    ** Including session moves, stock more than doubled YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))